Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 7/20 | 0.50 |
| ▸ | ALPL | P05186 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 6/20 | 0.45 |
| ▸ | CA6 | P23280 | 3/20 | 0.45 |
| ▸ | CA9 | Q16790 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA7 | P43166 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | SLC22A12 | Q96S37 | 3/20 | 0.45 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29469931 | 1.00 | PTGES2 (0.55) | PTGES2CA2ALPLCA1CA6 | |
| Hydrochloric Acid SCHEMBL4436765 | 0.98 | PTGES2 (0.53) | PTGES2CA2ALPLCA1CA6 | |
| Hydrochloric Acid SCHEMBL29995248 | 0.98 | PTGES2 (0.53) | PTGES2CA2ALPLCA1CA6 | |
| SCHEMBL29995144 | 0.85 | PTGES2 (0.46) | PTGES2CA2ALPLCA1CA9 | |
| SCHEMBL10639576 | 0.85 | CA2 (0.47) | PTGES2CA2ALPLCA1CA6 | |
| SCHEMBL10691561 | 0.84 | PTGES2 (0.48) | PTGES2CA2CA1CA6CA9 | |
| SCHEMBL11054429 | 0.84 | CA2 (0.46) | PTGES2CA2ALPLCA1CA6 | |
| SCHEMBL6972429 | 0.82 | ALPL (0.47) | PTGES2ALPLSLC22A12SLC40A1HTR6 | |
| SCHEMBL17595937 | 0.82 | CA2 (0.47) | PTGES2CA2CA1CA6CA9 | |
| SCHEMBL3528957 | 0.82 | ELANE (0.60) | PTGES2ALPLSLC22A12SLC40A1HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 342 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | Alesta Therapeutics BV (NL) | 2026-05-19 | — | — | US | claimed |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | GENECODE (EE) | 2026-01-22 | — | — | US | claimed |
| EP-4492406-B1 | BIO-ELECTRODE COMPOSITION, BIO-ELECTRODE, METHOD FOR MANUFACTURING BIO-ELECTRODE | SHINETSU CHEMICAL CO (JP) | 2025-11-19 | — | — | EP | claimed |
| US-20250060669-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-02-20 | — | — | US | claimed |
| US-20250044687-A1 | RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-02-06 | — | — | US | claimed |
| US-20250032026-A1 | Bio-Electrode Composition, Bio-Electrode, Method For Manufacturing Bio-Electrode | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-01-30 | — | — | US | claimed |
| CN-119356028-A | Resist material and pattern forming method | 信越化学工业株式会社 | 2025-01-24 | — | — | CN | claimed |
| EP-4492406-A1 | BIO-ELECTRODE COMPOSITION, BIO-ELECTRODE, METHOD FOR MANUFACTURING BIO-ELECTRODE | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2025-01-15 | — | — | EP | claimed |
| CN-119286175-A | Bioelectrode composition, bioelectrode, and bioelectrode manufacturing method | 信越化学工业株式会社 | 2025-01-10 | — | — | CN | claimed |
| WO-2024028808-A1 | AROMATIC COMPOUNDS FOR USE AS PROTEIN PHOSPHATASE 2A (PP2A) MODULATORS | RAPPTA THERAPEUTICS OY (FI) | 2024-02-08 | — | — | WO | claimed |
| WO-2002092557-A1 | METHOD FOR PRODUCING 2-TRIFLUOROMETHOXY-BENZOLE SULPHONAMIDE | BAYER CROPSCIENCE AG (DE) | 2002-11-21 | — | — | WO | claimed |
| WO-2002085891-A1 | 2,6-SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA-3 ADRENORECEPTOR AGONISTS | BAYER PHARMACEUTICALS CORPORATION (US) | 2002-10-31 | — | — | WO | claimed |
| WO-2002006223-A1 | 1,3-DISUBSTITUTED AND 1,3,3-TRISUBSTITUTED PYRROLIDINES AS HISTAMINE-3 RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ABBOTT LABORATORIES (US) | 2002-01-24 | — | — | WO | claimed |
| WO-2001090090-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB (SE) | 2001-11-29 | — | — | WO | claimed |
| EP-0863869-B1 | METHOD OF PREPARING 2-TRIFLUOROMETHOXYBENZENE SULPHONAMIDE | BAYER AG (DE) | 2000-08-16 | — | — | EP | claimed |
| JP-2000500756-A | — | — | 2000-01-25 | — | — | JP | claimed |
| US-5925788-A | Method of preparing 2-trifluoromethoxy-benzenesulphonamide | BAYER AKTIENGESELLSCHAFT (DE) | 1999-07-20 | — | — | US | claimed |
| EP-0863869-A1 | METHOD OF PREPARING 2-TRIFLUOROMETHOXYBENZENE SULPHONAMIDE | BAYER AG (DE) | 1998-09-16 | — | — | EP | claimed |
| WO-1997019056-A1 | METHOD OF PREPARING 2-TRIFLUOROMETHOXYBENZENE SULPHONAMIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1997-05-29 | — | — | WO | claimed |
| EP-0173312-A1 | 1-(2-Trifluoromethoxy-phenylsulfonyl)-3-heteroaryl-(thio) ureas | BAYER AG (DE) | 1986-03-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630529-B2 | GCN2 modulator compounds | NR3C1, GCN1, EIF2AK4 | PTGES2 2076/4885CA2 1341/4885ALPL 4801/4885 |
| US-20260022096-A1 | NOVEL SULFONAMIDES AND THEIR USE AS NEUROPROTECTIVE AND/OR NEURORESTORATIVE AGENTS | CNR1, CDR2, SMN1; SMN2 | PTGES2 3209/4885CA2 240/4885ALPL 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.